Eurocor Tech - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.

Eurocor participates CIRSE Congress in Lisbon

Date: 2012/09/13

Visit our Exhibition Stand 38 at the International Congress Cardiovascular and Interventional Radiological Society of Europe (CIRSE)

Eurocor will be present at the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Lisbon, Portugal. CIRSE congress 2012 is dedicated to improve patient care through the support of teaching, science, research and clinical practice in the field of cardiovascular and interventional radiology from September 15th – 19th 2012. Eurocor is looking forward to show visitors innovative endovascular devices such as FREEWAY™ 014 and 035 peripheral drug-eluting balloon.

The coating makes the difference. Eurocor drug-eluting balloons have a unique homogeneous coating. The coating done by Eurocor consists of a 1:1 mixture of Shellac and Paclitaxel. The natural resin of Shellac is broad on the balloon in a 1:1 mixture and hardens the balloon surface. Due to this effect the Eurocor drug-eluting balloons are non-crystalline and are showing nearly no wash out effect.
FREEWAY™ uses the same technology as Eurocor’s DIOR® paclitaxel-eluting coronary balloon but applies it to a new patient population. Eurocor’s latest second-generation drug-eluting technology PTA balloon FREEWAY™ has been developed as an alternative to address the limitations of existing therapeutic to PAD e.g. restenosis after POBA or stenting (ISR) . FREEWAY™ is available in two versions: 014 and 035.
FREEWAY™ 035 is designed for the treatment of femoropopliteal arteries where the use of stents can be limited by the occurrence of high restenosis rates and anatomical challenges.
In addition Eurocor offers a full dedicated product line for below the knee artery treatment, FREEWAY™ 014 for the treatment of patients with Critical Limb Ischemia (CLI) where stenting is not a suitable solution for the lesion.
Meet Eurocor in Portugal at CIRSE 2012.
Further information on and

Press Release: DEAR Registry published online ahead of print